Jon Rousseau

President and CEO

BrightSpring Health Services

Sep 2016 - Current (10 years)

BrightSpring Health Services combined with PharMerica Corporation in early 2019 and is one of the largest health services companies in the U.S., as a leading pharmacy solutions company and home and community based health services provider. The company serves the largest populations in U.S. healthcare and provides clinical, pharmacy, and non-clinical services to complex Seniors, Specialty, and Behavioral individuals. Through its overlapping pharmacy and provider services that customers receive, the company is continuing to build upon its unique platform of high quality and integrated offerings, which provide significant value to the healthcare system, patients, and families. PharMerica is a leading U.S. pharmacy services provider to the

Executive Vice President, Kindred; President, Kindred Rehabilitation Services

Kindred

Mar 2015 - Aug 2016 (1 year 6 months)

Led the $2 billion Rehab Division at Kindred - the largest rehabilitation company in the United States by sites of service, with over 25,000 employees / caregivers in over 2,300 locations - consisting of 7 business segments, including freestanding IRFs (inpatient rehabilitation facilities ("rehab hospitals")) subsequent to the Centerre acquisition (January, 2015), acute rehab units in hospitals, outpatient rehab clinics, contract therapy in med/surg units of hospitals, long-term hospitals, skilled nursing facilities, and assisted / independent living facilities, 3rd party Part B therapy billing, and therapist staffing. The second largest freestanding IRF company (with a unique joint venture model consisting of partnerships with leading hos

President, Care Management Division

Kindred

Jul 2013 - Apr 2015 (1 year 10 months)

Led the Care Management division (including the Home Health & Hospice business, Home Based Primary Care, and integrated care management platforms and business models) with its 10,000 employees and healthcare professionals in 170 sites across the country. Completed and integrated numerous acquisitions, including Gentiva, and oversaw dramatic growth in the division. Reported to the President and COO and member of the Executive Committee of Kindred (NYSE: KND; 70,000 employees operating in 46 states).

Global Vice President, Marketing, Strategy and Commercial Development; Co-Lead Business Unit

Mylan Specialty

Sep 2012 - Jun 2013 (10 months)

Led global marketing, strategy and commercial development for Mylan Specialty and co-led billion dollar division in the Office of the President. Business unit sold all of Mylan’s branded products across consumer, office based physician, hospital, pharmacy, and payor channels in the allergy, respiratory, anesthesia, pain, and CNS therapy areas today. Led function (managing five brands, including EpiPen) consisting of strategy, business development, product planning, brand management, DTC (direct-to-consumer), digital, market expansion, professional affairs, public relations, advocacy, market research, managed markets, marketing operations, and sales effectiveness activities. Co-led organization decision making.

Vice President, Marketing and Strategy, Mylan North America

Mylan

May 2011 - Sep 2012 (1 year 5 months)

Led Marketing and Strategy (and various Sales initiatives) for Mylan’s North American platform ($3 billion business supplying 1 in 10 U.S. prescriptions) covering branded, branded generic, and generic products across four businesses, multiple channels (retail and specialty pharmacy, office based physicians, hospital, and payers), multiple technologies (oral solid, liquid capsule, transdermal, injectable, and inhalable), and 20 therapeutic categories. Ran strategy processes and ongoing strategic evaluations, including preparing for and defining biogeneric initiatives. Strategies and tactics included launching a new global master brand, launching numerous milestone products, and growing share of existing products.

Global Senior Director - Continuous Glucose Monitoring and Connectivity

Medtronic

Jan 2008 - May 2011 (3 years 5 months)

Led commercial activities for the Continuous Glucose Monitoring (“CGM”) and Connectivity business (six product lines) at the world’s leading medical device company (and at the $1.3 billion division). Managed both upstream Product Planning (new product definition and developments) and downstream Product Marketing (market research, brand management (STP, core message platform, creative execution), market development, direct-to-consumer, product/customer education, competition, pricing, forecasting, sales integration, training and support) teams to grow existing products and launch new products. CGM coordination over R&D, Manufacturing, Quality, Clinical, Regulatory, Customer Service, Education, and Sales. Lean Sigma and QFD (Quality Functi

Business Development Lead

Medtronic

Jan 2006 - Dec 2008 (3 years)

Created, prioritized and executed on strategies and growth initiatives in driving business development activities for multiple divisions ($1.5 billion) of the company. Performed diligence on and executed supply, joint development, license, distribution, and commercialization agreements, equity investments, new company formations, acquisitions, and (EU) divestitures in both medical devices and drug/device combination therapies. Venture Manager for partnered projects encompassing novel therapies. Core Team for development of new drug/device therapy. Led portfolio prioritization process and Research, Engineering, Clinical, and Manufacturing teams in product, market and financial assessments to execute milestone based business plans. Co-le

Senior Associate (Private Equity)

FFL Partners

Jan 2002 - Dec 2005 (4 years)

One of ten professionals investing an $800 million second private equity fund ($1.2 billion assets under management at the time) focused on leveraged acquisitions of growth companies and growth equity investments. Led cross-functional deal teams in executing transactions. Conducted business due diligence, structured investments and drafted proposals, developed detailed financial analyses and operating scenarios, negotiated deal documents, and coordinated debt financings and legal and accounting reviews. Evaluated markets and company strengths and weaknesses in due diligence, conducted detailed product, marketing, R&D, customer, supply chain, and facility reviews, assessed value propositions and management. Supported and developed portfo

Associate (Private Equity)

FFL Partners

Jan 1998 - Dec 2000 (3 years)

Worked closely with firm’s four founding Partners (as first hire after formation) since inception of inaugural $350 million private equity fund. Involvement in all aspects of leveraged buyout and equity investment activities across a wide range of industries. Portfolio company interim CFO and Board Member. Led portfolio company budgets and strategies.

Analyst (Investment Banking) - M&A and Principal Real Estate

Morgan Stanley

Jan 1996 - Dec 1998 (3 years)

Financial Analyst, Investment Banking Division, Mergers & Acquisitions: Financial Institutions Group. Analyzed and executed mergers, acquisitions and divestitures for major financial institutions. Responsibilities included detailed valuation, analysis of financial impact and evaluation of strategic alternatives for financial institutions. Closed multiple sellside acquisitions that were the largest ever at the time. Provided M&A analysis for confidential Morgan Stanley strategic initiatives. Financial Analyst, Investment Banking Division, Real Estate Group. Evaluated principal investments for $1.5 billion real estate merchant banking fund. Performed M&A advisory, refinancings and equity offerings for REITs.

About

Detail

Timeline

Résumé